TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01562132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine and fluconazole
Description: Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
Study: NCT03969706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 MG
Description: Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
Study: NCT04592276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: Participants took two capsules with PS128 after dinner for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants took two capsules without PS128 after dinner for 30 days.
Study: NCT03334708

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor Tissue Collection
Description: Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor Tissue Collection
Description: Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere

Intervention type: DIAGNOSTIC_TEST
Intervention: Cyst Fluid
Description: Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
Study: NCT02971787

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Day 1-21: 2 capsules per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt
Description: Day 8-21: 10 tablets à 600 mg per day
Study: NCT03856034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopy
Description: Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).
Study: NCT03632694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching and Tech Support
Description: Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tech Support Only
Description: Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching.
Study: NCT02712294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Study: NCT02876133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narrow band imaging withdrawal
Description: colonoscope withdrawal and mucosal inspection performed under narrow band imaging

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: white light withdrawal
Description: colonoscope withdrawal and mucosal inspection performed under white light imaging
Study: NCT03864458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration
Study: NCT02484573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Study: NCT02664636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.~This is part of routine care.
Study: NCT04269200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: Olaparib tablets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: durvalumab placebo
Description: Matching placebo for intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olaparib placebo
Description: Placebo tablets to match olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib placebo
Description: Placebo tablets to match olaparib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care chemotherapy
Study: NCT01599832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo dynamic contrast-enhanced magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study: NCT01721707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost+Brinzolamide combination
Description: 1 drop in each eye, 1x/day, at 9PM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: 1 drop in each eye, 1x/day, at 9PM
Study: NCT04269200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard of care chemotherapy
Study: NCT02459652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy is delivered with \>6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
Study: NCT04595604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trimodal rehabilitation + ERAS
Description: Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
Study: NCT03864458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration
Study: NCT04595604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERAS + nutritional prehabilitation
Description: Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
Study: NCT00667602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 (two doses)
Description: Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenC
Description: One 0.5mL dose of MenC vaccine was administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7
Description: One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7
Description: One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV7
Description: One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV-HepB-Hib
Description: One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV-HepB-Hib
Description: One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-IPV-HepB-Hib
Description: One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 (one dose)
Description: One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
Study: NCT02698059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNAP® Sleep Therapy System (iNAP)
Description: The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
Study: NCT03136302

Intervention type: PROCEDURE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation

Intervention type: PROCEDURE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation

Intervention type: PROCEDURE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation
Study: NCT02452593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tibial stimulation and pelvic floor exercises
Description: A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tibial stimulation and pelvic floor exercises
Description: A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
Study: NCT03165695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
Study: NCT02442531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CriPec® docetaxel
Description: -3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
Study: NCT02800746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline 100 ml is intravenously administered on 7-10 day before surgery
Study: NCT01946646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1-CCRT
Study: NCT03376412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
Study: NCT01893099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioembolization with SIR-Spheres® (Yttrium Microspheres)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioembolization with SIR-Spheres® (Yttrium Microspheres)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioembolization with SIR-Spheres® (Yttrium Microspheres)
Study: NCT01270061

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing
Description: HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Screen
Description: A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
Study: NCT01812772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double J-stent with a long tether
Description: Patients will receive a double-J stent placement with a long tether following ureteroscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double J-stent without a long tether
Description: Patients will receive a double-J stent placement without a long tether following ureteroscopy.
Study: NCT03789084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive-Behavioral Therapy for Health Anxiety
Description: 4-session in-person 45-minute psychotherapy sessions focused on building motivation for change, psychoeducation, cognitive restructuring, and situational and interoceptive exposure to health-related fear stimuli.
Study: NCT03864458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT03239145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
Study: NCT03789084

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referral to mental health provider
Description: Provider makes a referral to a mental health provider in the outpatient psychiatry clinic or a community provider of the participant's choice.
Study: NCT03328520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WILD 5 Wellness Intervention
Description: Behaviors in 6 areas of wellness: Sleep, Social Connectedness, Exercise, Nutrition, Mindfulness and HERO (Happiness, Enthusiasm, Resilience, Optimism)
Study: NCT03318913

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5g of the sucralose administered as white plastic capsules
Study: NCT01893099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioembolization with SIR-Spheres® (Yttrium Microspheres)
Study: NCT03239145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
Study: NCT03318913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fish protein hydrolysates
Description: 5g of the FPH dissolving in 100 mL of water
Study: NCT03239145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
Study: NCT01726257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellix System
Description: Subjects in this study will receive a Nellix Endovascular Sealing System as part of their intervention.
Study: NCT00781079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumer Provider
Description: Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
Study: NCT00879684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVX-060
Description: Weekly, intravenous dose
Study: NCT04993417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery technique along with EMS
Description: All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mime Therapy along with EMS
Description: All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
Study: NCT01446003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8457
Description: 10 x 10-mg capsule BID for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8457
Description: 10 x 10-mg capsule BID for 10 days
Study: NCT04194606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of radial artery for access for a coronary angiography or intervention
Description: After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of radial artery for access for a coronary angiography or intervention
Description: After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
Study: NCT02036749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: quadratus lumborum block

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nerve block
Description: quadratus lumborum block
Study: NCT00640393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50 mg, subcutaneous (SC) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50 mg, subcutaneous (SC) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50 mg, subcutaneous (SC) injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nbUVB
Study: NCT02098486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT04323215

Intervention type: DEVICE
Intervention: Support system
Description: A support system named Provement will be used to provide behavioral treatment.
Study: NCT02098486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone